Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2020
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in peripheral T-cell lymphoma (PTCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Response Rate at 20 weeks. Started Jan 2020; status: recruiting.
02
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05182957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182957.